Physician profile
Matthew Floyd
NPI 1245751106
$2,086.44
in general payments reported to CMS, 2019-2025
14 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $420 · 2023: $544 · 2024: $663 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $326.96 | 2022-2025 | Tyrvaya |
| Bausch & Lomb Americas INC. | $318.33 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Alcon Vision LLC | $313.01 | 2022-2025 | Rocklatan, Clareon, Tryptyr |
| Glaukos Corporation | $264.61 | 2023-2024 | Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Abbvie INC. | $227.21 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $166.23 | 2022-2025 | Tecnis Simplicity, Tecnis Iol, Veritas Vision System |
| Novartis Pharmaceuticals Corporation | $102.79 | 2022-2023 | |
| Horizon Therapeutics Plc | $101.60 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $78.74 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $76.18 | 2022-2025 | |
| Harrow Eye, LLC | $35.60 | 2025 | Vevye |
| Amgen INC. | $28.34 | 2025 | Tepezza |
| Rxsight INC | $23.52 | 2022 | |
| Ani Pharmaceuticals, INC. | $23.32 | 2025 | Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Floyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.